Does insurance cover plasma exchange, or is it cash-pay for longevity?
Insurance pays for therapeutic plasma exchange only when a diagnosis meets the payer's criteria. Medicare's national policy lists 13 indications, and private insurers such as Cigna use their own medical-necessity lists, often requiring preauthorization. Longevity and detox uses are not covered, so clinics charge cash, with single-session TPE prices from about $3,500 to $12,000.
Nov 17, 2026Updated Nov 18, 20268 min read

Insurance covers therapeutic plasma exchange (TPE), which removes a patient's plasma and replaces it, mainly for specific diagnosed diseases. Medicare covers 13 listed indications nationally, such as Guillain-Barré syndrome and myasthenia gravis. Local contractors may cover others case by case, and private insurers apply their own medical-necessity criteria. Longevity and "detox" uses are not covered, so clinics sell them for cash, from about $3,500 to $12,000 per TPE session.
Which conditions does Medicare cover for plasma exchange?
Medicare's national policy covers apheresis for 13 listed indications, and local Medicare contractors can approve others case by case. The policy is National Coverage Determination 110.14, in effect since 07/30/1992.
The 13 covered indications are:
- Acquired myasthenia gravis
- Leukapheresis for leukemia
- Waldenström's macroglobulinemia
- Hyperglobulinemias and hyperviscosity syndromes
- Thrombotic thrombocytopenic purpura (TTP), as a last resort
- Life-threatening rheumatoid vasculitis, as a last resort
- Charcoal-filter plasma perfusion for itching in cholestatic liver disease
- Goodpasture's syndrome
- Anti-GBM glomerulonephritis with advancing renal failure or pulmonary hemorrhage
- Chronic relapsing polyneuropathy with severe or life-threatening symptoms that has failed conventional therapy
- Life-threatening scleroderma or polymyositis, when unresponsive to conventional therapy
- Guillain-Barré syndrome
- Life-threatening lupus (SLE), as a last resort
Medicare also sets a rule about where treatment happens. It is covered only in a hospital, or in a physician-directed clinic where a physician is present at all times during patient care hours, each patient is under a physician's care and nonphysician services are under a physician's direct, personal supervision.
The AABB, a blood and biotherapies professional body, notes that the NCD "has not been updated since 1992". The American Society for Apheresis (ASFA), by comparison, grades conditions one by one, and its Tenth Edition guidelines contain 183 graded and categorized indications. The AABB adds that Medicare coverage is not limited to the NCD list. Decisions on other indications are made locally and may vary by contractor.
Traditional Medicare contractors do not require prior authorization for apheresis, according to ASFA's reimbursement guide, which was written by ASFA's advocacy committee and is hosted on the site of device maker Terumo BCT. Coverage is based on the NCD, a Local Coverage Determination, or individual consideration.
How do private insurers decide whether to cover plasma exchange?
Private insurers cover plasma exchange when the diagnosis appears on their medical-necessity list, and they commonly require approval before treatment. According to a 2023 AABB review of their policies, the apheresis policies UnitedHealthcare, Aetna and Cigna updated in 2023 list more than twice as many covered indications as the Medicare NCD. Preauthorization is commonly required by commercial insurers and Medicaid programs before outpatient procedures.
Cigna's current Medical Coverage Policy 0153 shows how these policies work:
- It took effect on 6/15/2026.
- It names conditions for which plasmapheresis is a medically necessary primary therapy, including Guillain-Barré syndrome and TTP.
- It treats any other indication as not medically necessary, and names Alzheimer's disease.
- The customer's own benefit plan document supersedes the policy when the two conflict.
- Plasma exchange is billed under CPT code 36514.
A matching diagnosis is not always enough. Apheresis is often covered only if the patient meets additional laboratory, diagnostic or clinical criteria. When published evidence is suggestive but inconclusive, coverage may be decided case by case.
A covered course also looks different from a wellness package. For rheumatic disease, the American College of Rheumatology describes sessions every 2 to 3 days over 5 to 10 sessions, typically in a hospital or infusion center.
Why is plasma exchange for longevity or "detox" not covered?
Longevity and detox uses appear neither on Medicare's list nor on payers' medical-necessity lists, and the evidence for them is limited. The research falls into three groups.
Established: indications in Category I (first-line) or Category II (second-line) of ASFA's Ninth Edition guidelines, which Cigna's policy links to coverage, such as the diseases listed above. ASFA also grades uses it considers unestablished or ineffective, so a condition appearing in its guidelines is not the same as an established use.
Emerging, with small or mixed studies:
- Alzheimer's disease. The AMBAR trial found 52% less decline on one daily-living scale (P = .03) and only a trend on a cognitive scale (P = .06). It found no changes in mild-AD patients, and the investigators received funding from Grifols, a plasma products company.
- Microplastics. One uncontrolled 2026 study, by authors affiliated with Circulate Health, reported that circulating microplastics are reduced by TPE. It measured blood levels, not health outcomes, and also found that microplastics leach back into the blood from the plastic tubing set. A second 2026 paper reported preliminary observations after double filtration plasmapheresis, not TPE, and its authors concluded that larger, well-designed clinical trials are needed.
Unproven:
- Longevity and "biological age." An Aging Cell trial randomized 42 individuals and reported 15 epigenetic clocks showing rejuvenation compared with placebo. Epigenetic clocks are lab estimates of biological age; a change in a clock is not evidence of longer life or fewer diseases. Several authors are members of Circulate Inc., including its co-founder, a company in this field.
- Long COVID. A randomized trial found no differences between groups in any efficacy measure.
Does insurance cover INUSpheresis or double filtration plasmapheresis?
INUSpheresis, which its providers describe as a form of double filtration plasmapheresis (DFPP), has no clear route to coverage. Cigna's policy lists double filtration plasmapheresis among the procedures it does not address, and the billing code for filtration currently applies only to lipoprotein apheresis. Confirm with your own insurer before assuming otherwise.
DFPP filters a patient's plasma and returns it rather than replacing it. ASFA's reimbursement guide lists CPT 36516 for selective filtration with plasma reinfusion. It says the code applies only to lipoprotein apheresis for now, and that other selective filtration procedures may fall under it if approved for clinical use in the future.
See INUSpheresis vs plasma exchange for how the methods differ, and INUSpheresis cost for pricing detail.
What does plasma exchange cost if you pay cash?
For TPE, single-session cash prices run from $3,500 for a low-volume session to $12,000, as of November 18, 2026. Clinics are listed alphabetically; the order is not a ranking.
| Clinic | Treatment | Price |
|---|---|---|
| Apeiron Center | Low-volume (1 liter) TPE session | USD 3,500 |
| Extension Health | TPE session | USD 12,000 |
Before you compare, ask each clinic what the price includes: lab tests, replacement fluids, physician time and the number of sessions. For how these figures break down, see what plasma exchange costs, clinic by clinic.
Can you use an HSA or FSA, or deduct the cost?
For longevity or wellness treatment, eligibility is uncertain, and only your plan administrator and tax adviser can confirm it. The 2021 edition of IRS Publication 502 says medical care must be primarily to alleviate or prevent a physical or mental disability or illness, and excludes expenses that are "merely beneficial to general health." Check the current edition before you rely on it.
Treatment for a diagnosed disease fits that definition more easily than longevity treatment does. For HSAs, Publication 502 refers readers to Publication 969; ask your administrator whether a specific treatment qualifies and what documentation it needs.
Travel rules are narrow. Under the 2021 edition, lodging while away for medical care can count only if treatment is received from a doctor in a licensed hospital or an equivalent facility, and it is capped at $50 for each night for each person. The treatment itself must also qualify as medical care.
What paperwork and questions should you bring to your insurer and the clinic?
For a covered diagnosis, the key document is the preauthorization request your physician submits, addressing each of the insurer's criteria. For a cash purchase, you need an itemized record that an administrator or tax adviser can assess.
For a covered diagnosis
Ask your insurer which documents it needs, and ask your physician to address each lab, diagnostic and clinical criterion in the request. Request a copy of your plan document as well, since under Cigna's policy it supersedes the general policy.
For a cash-pay purchase
- An itemized invoice showing the procedure and its CPT code
- The treating physician's name and credentials
- Proof of the facility's licensure
- Any diagnosis recorded for the treatment
Questions to ask
Ask your insurer:
- Which apheresis policy applies to my plan, and what does my plan document say?
- Is my diagnosis listed, and what lab or clinical criteria apply?
- Is prior authorization required, and for how many sessions?
Ask the clinic:
- Which procedure is this, plasma exchange or filtration, and which CPT code will you bill?
- Is a physician present throughout treatment?
- What published evidence supports this use, and who funded it?
Ask your own physician, who knows your history, whether treatment makes sense for you.
Common questions
Does FDA clearance of the machine mean my use is approved?
No. The FDA cleared machines such as the Spectra Optia as a therapeutic blood cell and plasma separator, with a 2007 decision date. That clearance covers the device, not every use a clinic advertises. Insurers decide coverage by diagnosis and medical-necessity criteria, not by which machine a clinic uses.
Is young-donor plasma infusion the same as plasma exchange?
No. Young-donor plasma infusion gives a patient plasma from younger donors, while TPE removes the patient's own plasma and replaces it. They are separate practices. In 2019 the FDA warned that plasma is not FDA-approved to treat normal aging or memory loss.
Sources14 cited
- [1]NCD - Apheresis (Therapeutic Pheresis) (110.14) · cms.gov
- [2]payer-coverage-of-therapeutic-apheresis.pdf?sfvrsn=bf1fd837_1 · aabb.org
- [3]Tenth Edition guidelines contain 183 graded and categorized indications · doi.org
- [4]2024%20ASFA%20Therapeutic%20Apheresis%20Reimbursement%20Guide%20for%20TBCT%20Use.pdf · terumobct.com
- [5]mm_0153_coveragepositioncriteria_plasmapheresis.pdf · static.cigna.com
- [6]Plasma Exchange (Plasmapheresis) | American College of Rheumatology · rheumatology.org
- [7]A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. · doi.org
- [8]Can Plasma Exchange Be Used to Lower the Circulating Burden of Microplastics in Human Patients? · doi.org
- [9]larger, well-designed clinical trials are needed · doi.org
- [10]randomized 42 individuals and reported 15 epigenetic clocks showing rejuvenation compared with placebo · doi.org
- [11]Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial - Nature Communications · doi.org
- [12]p502--2021.pdf · irs.gov
- [13]510(k) Premarket Notification · accessdata.fda.gov
- [14]Important Information about Young Donor Plasma Infusions for Profit | FDA · fda.gov
For information, not medical advice. Suggest a correction · Editorial policy


